References

1. Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, obesity & metabolism 2016; 18: 783-94.
2. Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M, Mosenzon O, Kato E, Cahn A, Furtado R, Bhatt D, Leiter L, McGuire D, Wilding J, Sabatine M. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 2019; 393: 31-39.
3. Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D, Edwards R, Agarwal R, Bakris G, Bull S, Cannon C, Capuano G, Chu P, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler D, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner B, Mahaffey K. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine 2019; 380: 2295-306.
4. Bauersachs J, de Boer R, Lindenfeld J, Bozkurt B. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European heart journal 2022; 43: 367-76.
5. Mahaffey K, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews D. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137: 323-34.
6. Mahaffey K, Jardine M, Bompoint S, Cannon C, Neal B, Heerspink H, Charytan D, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler D, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner B, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation 2019; 140: 739-50.
7. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). In, 2017.
8. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine
canagliflozin (Invokana, Invokamet, Invokamet XR). In.
9. Fulcher G, Matthews D, Perkovic V, de Zeeuw D, Mahaffey K, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes, obesity & metabolism 2016; 18: 82-91.
10. Neal B, Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes care 2015; 38: 403-11.
11. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med 2018; 178: 1190-98.
12. Kavanagh N, Ryan E, Widaa A, Sexton G, Fennell J, O’Rourke S, Cahill K, Kearney C, O’Brien F, Kerrigan S. Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions. Clinical microbiology reviews 2018; 31.
13. Prokesch BC, TeKippe M, Kim J, Raj P, TeKippe EM, Greenberg DE. Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae. The Lancet Infectious Diseases 2016; 16: e190-e95.
14. Shone A, Burnside J, Chipchase S, Game F, Jeffcoate W. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. Diabetes care 2006; 29: 945.
15. Schwegler B, Stumpe K, Weishaupt D, Strobel K, Spinas G, von Schulthess G, Hodler J, Böni T, Donath M. Unsuspected osteomyelitis is frequent in persistent diabetic foot ulcer and better diagnosed by MRI than by 18F-FDG PET or 99mTc-MOAB. Journal of internal medicine 2008; 263: 99-106.
16. Newman L, Waller J, Palestro C, Schwartz M, Klein M, Hermann G, Harrington E, Harrington M, Roman S, Stagnaro-Green A. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991; 266: 1246-51.
17. Game F. Management of osteomyelitis of the foot in diabetes mellitus. Nat Rev Endocrinol 2010; 6: 43-7.
18. Lavery L, Armstrong D, Wunderlich R, Mohler M, Wendel C, Lipsky B. Risk factors for foot infections in individuals with diabetes. Diabetes care 2006; 29: 1288-93.
19. Katsuhara Y, Ikeda S. Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs. Clin Drug Investig 2021; 41: 235-43.
20. Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, Moretti U. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, metabolism, and cardiovascular diseases : NMCD 2018; 28: 533-42.
21. Min J, Osborne V, Kowalski A, Prosperi M. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System. Drug safety 2018; 41: 313-20.
22. Moreland-Head LN, Coons JC, Seybert AL, Gray MP, Kane-Gill SL. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. J Cardiovasc Pharmacol Ther 2021; 26: 341-48.
23. Bate A, Lindquist M, Edwards I, Olsson S, Orre R, Lansner A, De Freitas R. A Bayesian neural network method for adverse drug reaction signal generation. European journal of clinical pharmacology 1998; 54: 315-21.
24. Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, He Z, Zhao W, Chen C, Qiu K, Wu J. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. The Lancet Diabetes & Endocrinology 2020; 8: 192-205.
25. Bonora B, Raschi E, Avogaro A, Fadini G. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovascular diabetology 2021; 20: 39.
26. Pasquel F, Lansang M, Dhatariya K, Umpierrez G. Management of diabetes and hyperglycaemia in the hospital. The lancet Diabetes & endocrinology 2021; 9: 174-88.
27. Davies M, D’Alessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler D, Buse J. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461-98.
28. Ramsey S, Newton K, Blough D, McCulloch D, Sandhu N, Reiber G, Wagner E. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes care 1999; 22: 382-7.
29. Eckman M, Greenfield S, Mackey W, Wong J, Kaplan S, Sullivan L, Dukes K, Pauker S. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA 1995; 273: 712-20.
30. Kobayashi H, Fujita R, Hiratsuka S, Shimizu T, Sato D, Hamano H, Iwasaki N, Takahata M. Differential effects of anti-RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of Staphylococcus aureus-induced osteomyelitis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2022; 40: 614-23.
31. Zhang L, Wang Y, Zhao J, Li Y, Chen H. Sex Differences in Osteomyelitis of the Foot in Persons With Diabetes Mellitus: A Meta-Analysis. Wound management & prevention 2021; 67: 19-25.
32. Almenoff J, Pattishall E, Gibbs T, DuMouchel W, Evans S, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clinical pharmacology and therapeutics 2007; 82: 157-66.
33. Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf 2016; 15: 583-90.
34. Hou Y, Ye X, Wu G, Cheng G, Du X, He J. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf 2014; 13: 853-7.
35. Butalia S, Palda V, Sargeant R, Detsky A, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008; 299: 806-13.